Journal
BLOOD REVIEWS
Volume 26, Issue -, Pages S35-S39Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/S0268-960X(12)70011-5
Keywords
Beta-thalassemia; Fetal hemoglobin; HbF induction
Categories
Funding
- Medical Research Council [G0000111] Funding Source: researchfish
- Medical Research Council [G0000111] Funding Source: Medline
- MRC [G0000111] Funding Source: UKRI
Ask authors/readers for more resources
Patients with beta (beta)-thalassemia who have high levels of fetal hemoglobin (HbF) have less severe anemia and are often transfusion-independent. Therefore, augmentation of HbF production has been a longstanding therapeutic objective. Three classes of HbF-inducing agents have been investigated for the treatment of beta-thalassemia including chemotherapeutics, short-chain fatty acid derivatives, and recombinant erythropoietin. These agents have several different mechanisms of action and have been shown to increase total hemoglobin levels by 1-5 g/dL above baseline, but none has been able to sustain the therapeutic levels needed to maintain transfusion independence. Recent findings have provided new insights regarding HbF regulatory pathways, providing new opportunities for derepression of fetal globin gene expression and HbF induction. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available